Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 410-070-8 | CAS number: 141880-36-6 ACID RED HT 3728; ERIONYL RED HT 3728
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Based on negative outcomes in the bacterial reverse mutation assay, chromosomal aberration study and in the mammalian cell gene mutationa assay, the substance is considered as non genotoxic.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 16 October 2013 to 04 December 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5300 - In vitro Mammalian Cell Gene Mutation Test
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- (Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Germany)
- Type of assay:
- mammalian cell gene mutation assay
- Specific details on test material used for the study:
- Name: FAT 45155/E TE
Batch No.: BS-DUW 1120/004-01
Physical State at RT: solid (powder)
Colour: red in fine grained form; greenish black in coarse- grained form
Density: 1.74 (relative)
Active components: 74.4 %
Expiry Date: 15 August 2018
Storage Conditions: at room temperature - Target gene:
- hypoxanthine-guanine-phosphoribosyl-transferase (HPRT)
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Details on mammalian cell type (if applicable):
- -Type and identity of media: MEM
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes
- Periodically "cleansed" against high spontaneous background: yes - Metabolic activation:
- with and without
- Metabolic activation system:
- Liver S9 of Wistar Phenobarbital and ß-Naphthoflavone-induced rat liver S9 mix
- Test concentrations with justification for top dose:
- Pre-experiment for experiment I (with and without metabolic activation):
25, 50, 100, 250, 500, 1000, 1750, 2500, 3750, 5000 µg/mL
Pre-experiment for experiment II (only without metabolic activation, 20 h long-term exposure assay):
25, 50, 100, 250, 500, 1000, 1750, 2500, 3750, 5000 µg/mL
Experiment I
without metabolic activation: 7.4, 18.6, 37.2, 74.4, 186.0, 372.0, 446.4 and 520.8 µg/mL
and with metabolic activation: 25, 50, 100, 250, 500, 1000, 1750, 2500, 3750 and 5000 µg/mL
Experiment II
without metabolic activation: 50, 100, 200, 400, 600, 800, 1000, 1200, 1800 and 2000 µg/mL
and with metabolic activation: 35, 70, 150, 300, 600, 800, 1000, 4000 and 5000 µg/mL - Vehicle / solvent:
- Vehicle (Solvent) used: cell culture medium (MEM + 0 % FBS 4h treatment; MEM + 10 % FBS 20h treatment).
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- no
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- ethylmethanesulphonate
- Remarks:
- without metabolic activation; 300 µg/mL
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- no
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 7,12-dimethylbenzanthracene
- Remarks:
- with metabolic activation; 0.8 and 1.0 µg/mL
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: dissolved in medium
DURATION: 4 h (short-term exposure), 20 h (long-term exposure)
Expression time (cells in growth medium): 5 days
Selection time (if incubation with selection agent): about one week
SELECTION AGENT (mutation assay): rate experiments (I+II) with single exposure; 5 individual flasks were seeded and evaluated
NUMBER OF CELLS EVALUATED: 400000 cells per flask
DETERMINATION OF CYTOTOXICITY: Method: relative growth
Cells:
V79 cells in vitro have been widely used to examine the ability of chemicals to induce cytogenetic changes and thus identify potential carcinogens or mutagens. These cells are characterized by their high proliferation rate (12 - 14 h doubling time of the BSL BIOSERVICE stock cultures) and their high cloning efficiency of untreated cells, usually more than 50 %. These facts are necessary for the appropriate performance of the study. The V79 cells (ATCC, CCL-93) were stored over liquid nitrogen (vapour phase) in the cell bank of BSL BIOSERVICE. This allows the repeated use of the same cell culture batch in experiments. Each cell batch was routinely checked for mycoplasma infections (PCR). Thawed stock cultures were maintained in plastic culture flasks in minimal essential medium (MEM). For purifying the cell population of pre-existing HPRT- mutants cells were exposed to HAT medium containing 100 µM hypoxanthine, 0.4 µM aminopterin, 16 µM thymidine and 10.0 µM glycine for several cell doublings (2-3 days). - Evaluation criteria:
- A test is considered to be negative if there is no biologically relevant increase in the number of mutants.
There are several criteria for determining a positive result:
-a reproducible three times higher mutation frequency than the solvent control for at least one of the concentrations;
-a concentration related increase of the mutation frequency; such an evaluation may be considered also in the case that a three-fold increase of
the mutant frequency is not observed;
-if there is by chance a low spontaneous mutation rate in the corresponding negative and solvent controls a concentration related increase of the mutations within their range has to be discussed. - Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Experiment I without S9: ≥186.0 μg/mL and at 7.4 µg/mL; experiment I with S9: ≥1750 μg/mL and at 500 µg/mL; Experiment II without S9: ≥600 μg/mL; Experiment II with S9: ≥300 μg/mL
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: all strains/cell types tested
- Conclusions:
- FAT 45155/E is considered to be non-mutagenic in the HPRT locus using V79 cells of the Chinese Hamster.
- Executive summary:
In a GLP compliant study conducted according to OECD guideline 476 and EU method B.17, FAT 45155/E was assessed for its potential to induce mutations at the HPRT locus using V79 cells of the Chinese Hamster. The selection of the concentrations was based on data from the pre-experiments. Experiment I with and without metabolic activation and experiment II with metabolic activation were performed as a 4 h short-term exposure assay. Experiment II without metabolic activation was performed as 20 h long time exposure assay. The test item was investigated at the following concentrations:
Experiment I
without metabolic activation: 7.4, 18.6, 37.2, 74.4, 186.0, 372.0, 446.4 and 520.8 µg/mL and with metabolic activation: 25, 50, 100, 250, 500, 1000, 1750, 2500, 3750 and 5000 µg/mL
Experiment II without metabolic activation: 50, 100, 200, 400, 600, 800, 1000, 1200, 1800 and 2000 µg/mL and with metabolic activation: 35, 70, 150, 300, 600, 800, 1000, 4000 and 5000 µg/mL
No precipitation of the test item was noted in the experiments. Biologically relevant growth inhibition was observed in experiment I and II with and without metabolic activation. In experiment I without metabolic activation the relative growth was 11.2 % for the highest concentration (520.8 µg/mL) evaluated. The highest biologically relevant concentration evaluated with metabolic activation was 5000 µg/mL with a relative growth of 21.6 %. In experiment II without metabolic activation the relative growth was 10.2 % for the highest concentration (2000 µg/mL) evaluated. The highest concentration evaluated with metabolic activation was 5000 µg/mL with a relative growth of 19.2 %. In both experiments no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activation). No dose-response relationship was observed. DMBA and EMS were used as positive controls and showed distinct and biologically relevant effects in mutation frequency. In conclusion, FAT 45155/E is considered to be non-mutagenic in the HPRT locus using V79 cells of the Chinese Hamster.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 23 June 1992 to 17 December 1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.5375 (In Vitro Mammalian Chromosome Aberration)
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- other: MITI Japan Notification No. 303 (1987 / Lit. 10)
- Deviations:
- not specified
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
- Specific details on test material used for the study:
- Test article: FAT 45155/B
Trade name: ERIONYL ROT HT 3728
Batch No.: HT 3728/TV 1
Purity: 60 - 70 %
Physical properties: powder; dark red
Stability of the test material in the vehicle: stable
Expiration date: May 15, 1997 - Target gene:
- ATCC (American Type Culture Collection) CCL 61 (ovary, Chinese hamster)
- Species / strain / cell type:
- Chinese hamster Ovary (CHO)
- Details on mammalian cell type (if applicable):
- Cell line: ATCC (American Type Culture Collection) CCL 61 (ovary, Chinese hamster)
- Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- Rat-liver post mitochondrial supernatant (S9 fraction)
- Test concentrations with justification for top dose:
- Experiments without metabolic activation:
- 18 hours treatment time: 39.06, 78.13 and 156.25 μg/ml
- 42 hours treatment time: 78.13, 156.25 and 312.5 μg/ml
Experiments with metabolic activation:
-3 hours treatment followed by 15 hours recovery period: 78.13, 156.25 and 312.5 μg/ml
-3 hours treatment followed by 39 hours recovery period: 156.25, 312.5 and 625 μg/ml - Vehicle / solvent:
- Bidistilled water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- other: distilled water
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- mitomycin C
- Details on test system and experimental conditions:
- Preparation of the metabolic activation mixture:
Rat-liver post mitochondrial supernatant (S9 fraction) was prepared in advance from male RAI rats; reared at the Animal Farm of CIBA-GEIGY, Sisseln, Switzerland. The animals (150-250 g) were treated with Aroclor 1254 5 days prior to sacrifice. The livers were homogenized with 3 volumes of 150 mM KCl. The homogenate was centrifuged at 9000x g for 15 minutes and the resulting supernatant (S9 fraction) was stored at approximately -80 °C for no longer than one year. S9 fraction was thawed immediately before use, mixed with NADP and isocitric acid and added to culture medium to give the following final concentrations:
Rat liver S9 fraction 15 μl/ml (1.5 %)
NADP 3.14 μmol/ml
Isocitric acid (trisodium salt) 15.3 μmol/ml - Evaluation criteria:
- Under the standard conditions of our laboratories, the test substance is generally considered to be active in the Chinese Hamster cells if the following conditions are met:
- The percentage of metaphases containing specific aberrations in a treatment group is higher than 6.0 (based on historical negative control range) and differs statistically significant from the respective value of the negative control.
- A concentration-related response should be demonstrable. - Statistics:
- No data
- Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- at 156.25 μg/ml
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- No data
- Remarks on result:
- other: all strains/cell types tested
- Conclusions:
- FAT 45155/B considered as non-clastogenic in Chinese hamster ovary cells.
- Executive summary:
In a GLP-compliant study performed according to OECD guideline 473 and EU method EU B.10, FAT 45155/B was investigated for clastogenic (chromosome-damaging) effects on Chinese hamster ovary cells in vitro with and without extrinsic metabolic activation (S9) . The compound was dissolved in bi-distilled water and tested at each of the following conditions:
Experiments without metabolic activation:
- 18 hours treatment time:
original experiment: 39.06, 78.13 and 156.25 µg/ml
confirmatory experiment: 39.06, 78.13 and 156.25 µg/ml
- 42 hours treatment time: 78.13, 156.25 and 312.5 µg/ml
Final concentrations greater than 156.25 µg/ml (after 18 hours) or 312.5 µg/ml (after 42 hours) of culture medium could not be scored due to cytotoxicity. Mitomycin C (0.2 µg/ml) was used as a positive control in the 18 hours experiments.
Experiments with metabolic activation:
- 3 hours treatment followed by 15 hours recovery period:
original experiment: 78.13, 156.25 and 312.5 µg/ml
confirmatory experiment: 78.13, 156.25 and 312.5 µg/ml
- 3 hours treatment followed by 39 hours recovery period: 156.25, 312.5 and 625 µg/ml
Final concentrations greater than 312.5 µg/ml (after 18 hours) or 625 µg/ml (after 42 hours) of culture medium could not be scored due to cytotoxicity. Cyclophosphamide (20.0 µg/ml) was used as a positive control in the 3 hours/15 hours experiments. In addition, DNA distribution of cultures treated under the above described conditions (18 hours only) was determined by flow cytometry. These measurements allow to analyse the influence of the test substance on the cell cycle of CHO cells. In both the experiments performed without and with metabolic activation no significant increase in the number of metaphases containing specific chromosomal aberrations was observed. The incidence of aberrant cells was within the historical control range at all doses assessed.
Flow cytometry experiments did reveal evidence for very weak cell cycle disturbing activities of the test substance at the highest concentration in the presence of metabolic activation. However, the effects are considered to be of no relevance for the chromosome aberration assay. It is concluded that under the given experimental conditions no evidence of clastogenic effects was obtained in Chinese hamster ovary cells in vitro treated with FAT 45155/B.
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 June 1992 to 15 December 1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- other: MHW Japan 1984
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- other: EPA U.S.A 1987
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Specific details on test material used for the study:
- Test article: FAT 45155/B
Batch No.: HT 3728/TV 1
Purity: 60 - 70 %
Storage conditions: room temperature; keep dark
Stability of the test material in the vehicle: stable in bidistilled water
Expiration date: May 15, 1997 - Target gene:
- salmonella typhimurim histidine(his) reversion system
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Additional strain / cell type characteristics:
- not specified
- Species / strain / cell type:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Metabolic activation system:
- Rat-liver microsomal fraction S9
- Test concentrations with justification for top dose:
- Range finding test: 20.5761, 61.7284, 185.1852, 555.5556, 1666.6667 and 5000.0000 μg/plate
Mutagenicity test: 61.7284, 185.1852, 555.5556, 1666.6667 and 5000.0000 μg/plate - Vehicle / solvent:
- bidistilled water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- Experiment without microsomal activation: TA 100 and TA 1535
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 2-nitrofluorene
- Remarks:
- Experiment without microsomal activation: TA 98 and TA 1538
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- Remarks:
- Experiment without microsomal activation: TA1537
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- Remarks:
- Experiment without microsomal activation: WP2uvrA
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene
- Remarks:
- Experiment with microsomal activation: TA 100, TA 98, TA 1537, TA 1538 (2.5 µg/plate) and WP2uvrA (50 µg/plate)
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- Experiment with microsomal activation: TA 1535
- Details on test system and experimental conditions:
- Preparation of the bacterial cultures:
Inoculates from frozen master copies were set up monthly. They were grown in liquid NB-medium overnight and then plated on NB-agar. After incubation, single colonies were taken from the plates, grown overnight in liquid NB-medium and then used for the experiment.
Preliminary Toxicity/Range-Finding test:
A toxicity test was carried out with strain TA100 and E.COLI wp2uvrA without and with microsomal activation at six concentrations of the test substance and one negative control according to the standard operating procedures of genetic toxicology. The plates were inverted and incubated for about 48 hours at 37 ±1.5 °C in darkness.
Mutagenicity test:
The mutagenicity test was performed with strains TA 100, TA1535, TA 98, TA 1537 and E. coli WP2uvrA without and with microsomal activation according to standard operating procedures of genetic toxicology. The plates were inverted and incubated for about 48 hours at 37 ±1.5 °C in darkness. They were evaluated by counting the colonies and determine the background lawn. - Evaluation criteria:
- A doubling of the spontaneous reversion rate and a dose-effect relationship.
- Statistics:
- In deviation to the OECD guideline a statistical analysis was not perform. No appropriate statistical method is available.
- Species / strain:
- other: S. typhimurium TA 1535, TA 1537, TA 1538, TA100, TA 98 and E.coli
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: all strains/cell types tested
- Conclusions:
- The test substance and its metobolites did not induce gene mutations in the strains of S. typhimurium and E. coli.
- Executive summary:
A bacterial reverse mutation test with FAT 45155/B was carried out according to OECD guideline 471 and in compliance with GLP using in histidine-requiring strains of Salmonella typhimurium and a tryptophan-requiring strain of Escherichia coli. The concentration range of FAT 45155/B to be tested in the mutagenicity test was determined in a preliminary toxicity test. Thus, FAT 45155/B was tested for mutagenic effects without and with metabolic activation at five concentrations in the range of 61.7 to 5000 ug/plate. In order to confirm the results, the experiments were repeated in an independent experiment with the same concentrations. In a toxicity test/range finding test, no signs of toxicity of FAT 45155/B on the growth of the bacteria were observed up to the concentration of 5000 ug/ plate. While in the original mutagenicity test experiment performed without and with metabolic activation, none of the tested concentrations of FAT 45155/B led to an increase in the incidence of histidine- or tryptophanprototrophic mutants by comparison with the negative control. In the confirmatory experiment performed without and with metabolic activation, again, the tested concentrations of FAT 45155/B did not lead to an increase in the incidence of histidine- or tryptophan prototrophic mutants by comparison with the negative control. Based on the results of these experiments and on standard evaluation criteria, it is concluded that FAT 45155/B and its metabolites did not induce gene mutations in the strains of S. typhimurium and E. coli used.
Referenceopen allclose all
Precipitation:
No precipitation of the test item was noted in any of the experiments.
Toxicity:
A biologically relevant growth inhibition (reduction of relative growth below 70 %) was observed after the treatment with the test item in experiment I and II with and without metabolic activation.
In experiment I without metabolic activation the relative growth was 11.2 % for the highest concentration (520.8 µg/mL) evaluated. The highest biologically relevant concentration evaluated with metabolic activation was 5000 µg/mL with a relative growth of 21.6 %. In experiment II without metabolic activation the relative growth was 10.2 % for the highest concentration (2000 µg/mL) evaluated. The highest concentration evaluated with metabolic activation was 5000 µg/mL with a relative growth of 19.2 %.
Mutagenicity:
In experiment I without metabolic activation all mutant values of the negative controls and test item concentrations found were within the historical control data of the test facility BSL BIOSERVICE (about 5-43 mutants per 106 cells). No dose-response relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the negative controls. Mutation frequencies with the negative control were found to be 11.91 and 16.72 mutants/106 cells and in the range of 6.41 to 33.33 mutants/106 cells with the test item, respectively. The highest mutation rate (compared to the negative control values) of 2.33 was found at a concentration of 74.4 µg/mL with a relative growth of 76.2 %. With metabolic activation all mutant values of the negative controls and test item concentrations found were within the historical control data of the test facility BSL BIOSERVICE (about 5-44 mutants per 106 cells). No dose-response relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the negative controls. Mutation frequencies with the negative control were found to be 37.99 and 24.93 mutants/106 cells and in the range of 13.85 to 43.30 mutants/106 cells with the test item, respectively. The highest mutation rate (compared to the negative control values) of 1.38 was found at a concentration of 1750 µg/mL with a relative growth of 34.3%. In experiment II without metabolic activation most mutant values of the negative controls and test item concentrations found were within the historical control data of the test facility BSL BIOSERVICE (about 5-43 mutants per 106 cells). No dose-response relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the negative controls. Mutation frequencies with the negative control were found to be 22.63 and 25.81 mutants/106 cells and in the range of 15.05 to 58.90 mutants/106 cells with the test item, respectively. The highest mutation rate (compared to the negative control values) of 2.43 was found at a concentration of 100 µg/mL with a relative growth of 72.8 %. In experiment II with metabolic activation most mutant values of the negative controls and test item concentrations found were within the historical control data of the test facility BSL BIOSERVICE (about 5-44 mutants per 106 cells). No dose-response relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the negative controls. Mutation frequencies with the negative control were found to be 33.23 and 20.60 mutants/106 cells and in the range of 7.50 to 63.07 mutants/106 cells with the test item, respectively. The highest mutation rate (compared to the negative control values) of 2.34 was found at a concentration of 600 µg/mL with a relative growth of 19.3 %. DMBA (0.8 and 1.0 µg/mL) and EMS (300 µg/mL) were used as positive controls and showed distinct and biologically relevant effects in mutation frequency.
Experiment I -Toxicity, without metabolic activation
Dose Group | Concen-tration[µg/mL] | Cell Density[cells/mL]a | Relative Growth[%]a | Number of cells per flaskb | Cloning Efficiency[%] | ||
I | II | mean | |||||
NC1 |
0 | 891000 |
100.0 | 143 | 176 | 160 | 80 |
NC2 | 889000 | 141 | 146 | 144 | 72 | ||
1 | 7.4 | 512000 | 57.5 | 143 | 144 | 144 | 72 |
2 | 18.6 | 641000 | 72.0 | 141 | 151 | 146 | 73 |
3 | 37.2 | 671000 | 75.4 | 152 | 174 | 163 | 82 |
4 | 74.4 | 678000 | 76.2 | 171 | 177 | 174 | 87 |
5 | 186.0 | 441000 | 49.6 | 155 | 162 | 159 | 79 |
6 | 372.0 | 194000 | 21.8 | 148 | 157 | 153 | 76 |
7 | 446.4 | 127000 | 14.3 | 142 | 150 | 146 | 73 |
8 | 520.8 | 100000 | 11.2 | 147 | 165 | 156 | 78 |
EMS | 300 | 793000 | 89.1 | 135 | 137 | 136 | 68 |
NC: negative control/medium control
a: cell density and relative growth at 1st subcultivation
b: mean value of cells per flask/200
EMS: Ethyl methane sulfonate[300µg/ml]
Experiment I– Mutagenicity, without metabolic activation
Dose Group | Concen-tration[µg/mL] | Number of mutant colonies per flaska |
Mean |
SD | Mutant colonies per 106cellsb |
Mutation Factor | ||||
I | II | III | IV | V | ||||||
NC1 |
0 | 4 | 4 | 2 | 5 | 4 | 3.8 | 0.98 | 11.91 |
|
NC2 | 3 | 3 | 5 | 6 | 7 | 4.8 | 1.60 | 16.72 | ||
1 | 7.4 | 6 | 7 | 9 | 10 | 11 | 8.6 | 1.85 | 29.97 | 2.09 |
2 | 18.6 | 4 | 5 | 5 | 5 | 7 | 5.2 | 0.98 | 17.81 | 1.24 |
3 | 37.2 | 1 | 2 | 4 | 5 | 6 | 3.6 | 1.85 | 11.04 | 0.77 |
4 | 74.4 | 10 | 9 | 13 | 12 | 14 | 11.6 | 1.85 | 33.33 | 2.33 |
5 | 186.0 | 2 | 3 | 3 | 4 | 4 | 3.2 | 0.75 | 10.09 | 0.71 |
6 | 372.0 | 3 | 3 | 4 | 5 | 6 | 4.2 | 1.17 | 13.77 | 0.96 |
7 | 446.4 | 9 | 9 | 10 | 10 | 10 | 9.6 | 0.49 | 32.88 | 2.30 |
8 | 520.8 | 1 | 1 | 2 | 3 | 3 | 2.0 | 0.89 | 6.41 | 0.45 |
EMS | 300 | 80 | 86 | 89 | 96 | 109 | 92.0 | 9.94 | 338.24 | 23.62 |
NC: negative control/medium control
a: number of mutant colonies in flask I toV
b: mean mutant colonies x 106/ (400000 x Cloning Efficiency/100)
EMS: Ethylmethanesulfonate [300 µg/ml]
Experiment I- Toxicity, with metabolic activation
Dose Group | Concen-tration[µg/ml] | Cell Density[cells/ml]a | Relative Growth[%]a | Number of cells per flaskb | Cloning Efficiency[%] | ||
I | II | mean | |||||
NC1 |
0 | 1230000 | 100.8 | 189 | 190 | 190 | 95 |
NC2 | 1210000 | 99.2 | 149 | 188 | 169 | 84 | |
1 | 25 | 1270000 | 104.1 | 207 | 220 | 214 | 107 |
2 | 50 | 1180000 | 96.7 | 181 | 208 | 195 | 97 |
3 | 100 | 1110000 | 91.0 | 218 | 193 | 206 | 103 |
4 | 250 | 1180000 | 96.7 | 209 | 216 | 213 | 106 |
5 | 500 | 632000 | 51.8 | 214 | 177 | 196 | 98 |
6 | 1000 | 855000 | 70.1 | 209 | 215 | 212 | 106 |
7 | 1750 | 418000 | 34.3 | 193 | 195 | 194 | 97 |
8 | 2500 | 258000 | 21.1 | 185 | 198 | 192 | 96 |
9 | 3750 | 198000 | 16.2 | 187 | 197 | 192 | 96 |
10 | 5000 | 263000 | 21.6 | 201 | 189 | 195 | 98 |
DMBA | 0.8 | 894000 | 73.3 | 157 | 162 | 160 | 80 |
DMBA | 1.0 | 881000 | 72.2 | 162 | 182 | 172 | 86 |
NC: negative control/medium control
a: cell density and relative growth at 1st subcultivation
b: mean value of cells per flask/200
DMBA: 7,12-Dimethylbenz(a)anthracene[0.8 and 1.0 µg/mL]
Experiment I– Mutagenicity, with metabolic activation
Dose Group | Concen-tration[µg/ml] | Number of mutant colonies per flaska |
Mean |
SD | Mutant colonies per 106cellsb |
Mutation Factor | ||||
I | II | III | IV | V | ||||||
NC1 |
0 | 17 | 20 | 10 | 14 | 11 | 14.4 | 3.72 | 37.99 |
|
NC2 | 5 | 11 | 11 | 6 | 9 | 8.4 | 2.50 | 24.93 | ||
1 | 25 | 13 | 15 | 15 | 16 | 25 | 16.8 | 4.21 | 39.34 | 1.25 |
2 | 50 | 11 | 13 | 14 | 17 | 18 | 14.6 | 2.58 | 37.53 | 1.19 |
3 | 100 | 10 | 12 | 13 | 14 | 16 | 13.0 | 2.00 | 31.63 | 1.01 |
4 | 250 | 8 | 8 | 8 | 8 | 9 | 8.2 | 0.40 | 19.29 | 0.61 |
5 | 500 | 7 | 7 | 9 | 9 | 13 | 9.0 | 2.19 | 23.02 | 0.73 |
6 | 1000 | 11 | 14 | 14 | 15 | 23 | 15.4 | 4.03 | 36.32 | 1.15 |
7 | 1750 | 14 | 21 | 15 | 15 | 19 | 16.8 | 2.71 | 43.30 | 1.38 |
8 | 2500 | 6 | 7 | 8 | 9 | 12 | 8.4 | 2.06 | 21.93 | 0.70 |
9 | 3750 | 16 | 16 | 16 | 17 | 18 | 16.6 | 0.80 | 43.23 | 1.37 |
10 | 5000 | 4 | 5 | 5 | 6 | 7 | 5.4 | 1.02 | 13.85 | 0.44 |
DMBA | 0.8 | 40 | 28 | 27 | 34 | 34 | 32.6 | 4.72 | 102.19 | 3.25 |
DMBA | 1.0 | 37 | 38 | 32 | 32 | 33 | 34.4 | 2.58 | 100.00 | 3.18 |
NC: negative control/medium control
a: number of mutant colonies in flask I to V
b: mean mutant colonies x 106/ (400000 x Cloning Efficiency/100)
DMBA: 7,12-Dimethylbenz(a)anthracene [0.8 and 1.0µg/mL]
Experiment II -Toxicity, without metabolic activation
Dose Group | Concen-tration [µg/mL] | Cell Density [cells/mL]a | Relative Growth [%]a | Number of cells per flaskb | Cloning Efficiency [%] | ||
I | II | mean | |||||
NC1 |
0 | 1890000 |
100.0 | 196 | 184 | 190 | 95 |
NC2 | 1820000 | 199 | 204 | 202 | 101 | ||
3 | 50 | 1510000 | 81.4 | 158 | 161 | 160 | 80 |
4 | 100 | 1350000 | 72.8 | 152 | 157 | 155 | 77 |
5 | 200 | 1830000 | 98.7 | 169 | 169 | 169 | 85 |
6 | 400 | 1310000 | 70.6 | 174 | 195 | 185 | 92 |
7 | 600 | 1060000 | 57.1 | 190 | 196 | 193 | 97 |
8 | 800 | 1020000 | 55.0 | 163 | 175 | 169 | 85 |
9 | 1000 | 805000 | 43.4 | 200 | 174 | 187 | 94 |
10 | 1200 | 574000 | 30.9 | 176 | 153 | 165 | 82 |
13 | 1800 | 142000 | 7.7 | 191 | 173 | 182 | 91 |
14 | 2000 | 189000 | 10.2 | 150 | 136 | 143 | 72 |
EMS | 300 | 1490000 | 80.3 | 126 | 164 | 145 | 73 |
NC:negative control/medium control
a: cell density and relative growth at 1st subcultivation
b: mean value of cells per flask /200
EMS: Ethylmethanesulfonate[300µg/ml]
Experiment II–Mutagenicity, without metabolic activation
Dose Group | Concen-tration [µg/mL] | Number of mutant colonies per flaska |
Mean |
SD | Mutant colonies per 106 cellsb |
Mutation Factor | ||||
I | II | III | IV | V | ||||||
NC1 |
0 | 5 | 6 | 8 | 11 | 13 | 8.6 | 3.01 | 22.63 |
|
NC2 | 6 | 8 | 10 | 11 | 17 | 10.4 | 3.72 | 25.81 | ||
3 | 50 | 2 | 3 | 4 | 7 | 8 | 4.8 | 2.32 | 15.05 | 0.62 |
4 | 100 | 12 | 16 | 18 | 22 | 23 | 18.2 | 4.02 | 58.90 | 2.43 |
5 | 200 | 10 | 11 | 11 | 11 | 15 | 11.6 | 1.74 | 34.32 | 1.42 |
6 | 400 | 5 | 12 | 13 | 14 | 15 | 11.8 | 3.54 | 31.98 | 1.32 |
7 | 600 | 3 | 4 | 4 | 6 | 8 | 5.0 | 1.79 | 12.95 | 0.53 |
8 | 800 | 5 | 6 | 6 | 8 | 8 | 6.6 | 1.20 | 19.53 | 0.81 |
9 | 1000 | 4 | 6 | 8 | 9 | 11 | 7.6 | 2.42 | 20.32 | 0.84 |
10 | 1200 | 6 | 7 | 9 | 13 | 14 | 9.8 | 3.19 | 29.79 | 1.23 |
13 | 1800 | 6 | 7 | 10 | 11 | 15 | 9.8 | 3.19 | 26.92 | 1.11 |
14 | 2000 | 8 | 9 | 10 | 10 | 12 | 9.8 | 1.33 | 34.27 | 1.41 |
EMS | 300 | 228 | 200 | 217 | 184 | 237 | 213.2 | 19.11 | 735.17 | 30.36 |
NC: negative control/medium control
a: number of mutant colonies in flask I to V
b: mean mutant colonies x 106/ (400000 x Cloning Efficiency/100)
EMS: Ethylmethanesulfonate [300µg/ml]
Experiment II-Toxicity, with metabolic activation
Dose Group | Concen-tration [µg/mL] | Cell Density [cells/mL]a | Relative Growth [%]a | Number of cells per flaskb | Cloning Efficiency [%] | ||
I | II | mean | |||||
NC1 |
0 | 995000 |
100.0 | 157 | 168 | 163 | 81 |
NC2 | 902000 | 192 | 177 | 185 | 92 | ||
4 | 35 | 869000 | 91.6 | 186 | 179 | 183 | 91 |
5 | 70 | 961000 | 101.3 | 178 | 189 | 184 | 92 |
6 | 150 | 735000 | 77.5 | 182 | 186 | 184 | 92 |
7 | 300 | 510000 | 53.8 | 163 | 174 | 169 | 84 |
8 | 600 | 183000 | 19.3 | 191 | 180 | 186 | 93 |
9 | 800 | 170000 | 17.9 | 169 | 171 | 170 | 85 |
10 | 1000 | 123000 | 13.0 | 180 | 181 | 181 | 90 |
13 | 4000 | 95100 | 10.0 | 150 | 170 | 160 | 80 |
14 | 5000 | 182000 | 19.2 | 194 | 197 | 196 | 98 |
DMBA | 0.8 | 614000 | 64.7 | 167 | 170 | 169 | 84 |
DMBA | 1.0 | 612000 | 64.5 | 175 | 189 | 182 | 91 |
NC: negative control/medium control
a: cell density and relative growth at 1st subcultivation
b: mean value of cells per flask/200
DMBA: 7,12-Dimethylbenz(a)anthracene[0.8and1.0µg/mL]
Experiment II–Mutagenicity, with metabolic activation
Dose Group | Concen-tration [µg/mL] | Number of mutant colonies per flaska |
Mean |
SD | Mutant colonies per 106 cellsb |
Mutation Factor | ||||
I | II | III | IV | V | ||||||
NC1 | 0 | 9 | 11 | 11 | 11 | 12 | 10.8 | 0.98 | 33.23 |
|
NC2 | 5 | 7 | 7 | 8 | 11 | 7.6 | 1.96 | 20.60 | ||
4 | 35 | 3 | 4 | 4 | 10 | 11 | 6.4 | 3.38 | 17.53 | 0.65 |
5 | 70 | 7 | 9 | 9 | 10 | 14 | 9.8 | 2.32 | 26.70 | 0.99 |
6 | 150 | 7 | 9 | 9 | 10 | 19 | 10.8 | 4.21 | 29.35 | 1.09 |
7 | 300 | 6 | 7 | 8 | 9 | 13 | 8.6 | 2.42 | 25.52 | 0.95 |
8 | 600 | 15 | 23 | 23 | 25 | 31 | 23.4 | 5.12 | 63.07 | 2.34 |
9 | 800 | 4 | 4 | 4 | 5 | 6 | 4.6 | 0.80 | 13.53 | 0.50 |
10 | 1000 | 12 | 15 | 16 | 18 | 20 | 16.2 | 2.71 | 44.88 | 1.67 |
13 | 4000 | 0 | 2 | 3 | 3 | 4 | 2.4 | 1.36 | 7.50 | 0.28 |
14 | 5000 | 6 | 6 | 7 | 9 | 10 | 7.6 | 1.62 | 19.44 | 0.72 |
DMBA | 0.8 | 109 | 121 | 124 | 131 | 133 | 123.6 | 8.52 | 366.77 | 13.63 |
DMBA | 1.0 | 132 | 133 | 134 | 139 | 147 | 137.0 | 5.55 | 376.37 | 13.98 |
NC: negative control/medium control
a: number of mutant colonies in flask I to V
b: mean mutant colonies x 106/ (400000 x Cloning Efficiency/100)
DMBA: 7,12-Dimethylbenz(a)anthracene[0.8 and 1.0µg/mL]
Toxicity test
A first series of experiments have been performed using concentrations up to 5000 µg/ml.These experiments revealed strong cytotoxicity at concentrations of 156.25 µg/ml and higher in the absence of metabolic activation (18 hours) and at 625 µg/ml and higher in the presence of metabolic activation (3 hours/15 hours). No cells survived the treatment at these concentrations (data not shown on tables). Therefore, for the next series of experiments concentrations of 156.25 µg/ml (without activation) and 312.5 µg/ml (with activation) were selected as the highest.
The highest concentration of 156.25 µg/ml selected for analysis in the first experiment of the original study (without metabolic activation, 18 hours treatment) caused 16.7 % suppression of mitotic activity. The highest concentration of 312.5 µg/ml selected for analysis in the second experiment of the original study (with metabolic activation, 3 hours treatment/15 hours recovery) caused 20.0 % suppression of mitotic activity. In the 42 hours experiments of the confirmatory study concentration ranges were used up to 312.5 µg/ml (without metabolic activation) and up to 625 µg/ml (with metabolic activation). In the experiment without metabolic activation, concentrations up 312.5 µg/ml could be evaluated. The highest concentration caused 6.2 % suppression of mitotic activity. In the experiment performed with metabolic activation (3 hours treatment/39 hours recovery) concentration up to 625 µg/ml could be evaluated. The highest concentration caused 42.9 % suppression of mitotic activity.
Original mutagenicity study
In the experiment performed without metabolic activation (experiment 1, 18 hours treatment), 0 % of metaphases with specific chromosomal aberrations were detected in the negative control. At the concentrations of 39.06 µg/ml, 78.13 µg/ml and 156.25 Mg/ml 0 %, 1.0 % and 1.0 % of cells with specific chromosomal aberrations were found. In the experiment performed with metabolic activation (experiment 2, 3 hours treatment/15 hours recovery), 0 % of metaphases with specific chromosomal aberrations were seen in the negative control. At the concentrations of 78.13 µg/ml,156.25 µg/ml and 312.5 Mg/ml the respective values were 0 %, 1.0 % and 1.0 %. In both original experiments slight, statistically significant differences were obtained with the two higher concentrations when compared with their respective negative controls. These significances may be explained by the 0 % values obtained with the negative controls of these two experiments whereby just a small difference results in a significant response. However, since a frequency of 1 % metaphases with aberrations, as found for the treated groups, is well within the historical negative control range and far below the critical level of 6 % required for a positive response, these effects are considered to be of no biological relevance.
Confirmatory mutagenicity study
In the experiment performed without metabolic activation after 18 hours treatment (experiment 1), 0 % of metaphases with specific chromosomal aberrations were detected in the negative control. At the concentrations of 39.06 µg/ml/ 78.13 µg/ml and 156.25 µg/ml 0.5 %, 0.5 % and 0 % of cells with specific chromosomal aberrations were registered. In the experiment performed with metabolic activation after 3 hours treatment/15 hours recovery (experiment 2;), 0 % of metaphases with specific chromosomal aberrations were seen in the negative control. At the concentrations of 78.13 µg/ml, 156.25 Mg/ml and 312.5 µg/ml 0.5 %, 0.5 % and 0.5 % of cells showed specific chromosomal aberrations. In the experiment performed without metabolic activation after 42 hours treatment (experiment 3), 0 % of metaphases with specific chromosomal aberrations were detected in the negative control cultures. At the concentrations of 78.13 µg/ml, 156.2 5 µg/ml and 312.5 µg/ml the corresponding values were 1.5 %, 1.0 % and 0 %. In the experiment performed with metabolic activation after 3 hours treatment/39 hours recovery (experiment 4), 1.0 % of metaphases with specific chromosomal aberrations were registered in the negative control cultures. At the concentrations of 156.25 µg/ml, 312.5 µg/ml and 625 µg/ml 0 %, 0.5 % and 1.0 % of cells with specific chromosomal aberrations were found. None of these values showed a statistically significant difference when compared with their respective negative control. Unspecific chromosomal aberrations in the form of chromatid gaps found in all experiments were within the frequency generally observed.
Positive controls
The treatment of the cultures with mitomycin-C, 0.2 µg/ml and cyclophosphamide, 20.0 µg/ml, respectively, was followed by a high incidence of specific chromosomal aberrations in the experiments one and two of the original study (62.0 % and 46.0 %) and in the experiments one and two of the confirmatory study (28.0 % and 18.0 %).
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Two Ames tests, one chromosome aberration test and one HPRT mutation assay were performed according to OECD guidelines with GLP.
A key Ames study was performed to define the mutagenicity of the test substance with S. typhimurium strains TA 1535, TA 1537, TA 98 and TA 100 with and without metabolic activation based on OECD TG 471. There was no significantly difference for revertant between the negative controls and test groups at concentrations of 33.3; 100.0; 333.3; 1000.0; 2500.0 and 5000.0 μg/plate. It can be concluded that test substance cause no mutagenicity for S. typhimurium strains at all test concentrations. The other Ames test was performed to define the mutagenicity of the test substance with S. typhimurium strains TA 1535, TA 1537, TA 1538, TA 98, TA 100 and E.coli with and without metabolic activation based on OECD TG 471. There was no significantly difference for revertant between the negative controls and test groups at concentrations of 61.7284, 185.1852, 555.5556, 1666.6667 and 5000.0000 μg/plate. It can be concluded that test substance caused no mutagenicity for S. typhimurium strains and E.coli at all test concentrations.
The chromosomal aberration test (Dr. Th. Hertner, 1992) was performed according to OECD TG 473 to investigated for clastogenic (chromosome-damaging) effects on Chinese hamster ovary cells in vitro with and without extrinsic metabolic activation (S9). 39.06, 78.13 and 156.25 μg/ml were applied in the test without S9 and 78.13, 156.25 and 312.5 μg/ml were applied in the test with S9. In both the experiments performed without and with metabolic activation no significant increase in the number of metaphases containing specific chromosomal aberrations was observed. The incidence of aberrant cells was within the historical control range at all doses assessed. Therefore, it can be concluded that no clastogenic effects was observed in chinese hamster ovary cells in vitro treated with the test substance under the test condition.
In a GLP-compliant mammalian cell gene mutation assay, tested according to OECD guideline 476, Chinese hamster V79 cells were exposed to the test substance with and without metabolic activation and the potential to induce mutations at the HPRT locus was assessed. The selection of the concentrations was based on data from the pre-experiments. Experiment I with and without metabolic activation and experiment II with metabolic activation were performed as a 4h short-term exposure assay. Experiment II without metabolic activation was performed as 20h long time exposure assay. The following concentrations were used. Experiment I without metabolic activation: 7.4, 18.6, 37.2, 74.4, 186.0, 372.0, 446.4, and 520.8 µg/mL; Experiment I with metabolic activation: 25, 50, 100, 250, 500, 1000, 1750, 2500, 3750, and 5000 µg/mL; Experiment II without metabolic activation: 50, 100, 200, 400, 600, 800, 1000, 1200, 1800, and 2000 µg/mL; Experiment II with metabolic activation: 35, 70, 150, 300, 600, 800, 1000, 4000, and 5000 µg/mL. No precipitation was noted in the experiments. Biologically relevant growth inhibition was observed in experiment I and II with and without metabolic activation. In experiment I without metabolic activation the relative growth was 11.2 % for the highest concentration (520.8 µg/mL) evaluated. The highest biologically relevant concentration evaluated with metabolic activation was 5000 µg/mL with a relative growth of 21.6 %. In experiment II without metabolic activation the relative growth was 10.2 % for the highest concentration (2000 µg/mL) evaluated. The highest concentration evaluated with metabolic activation was 5000 µg/mL with a relative growth of 19.2 %. In both experiments no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activation). No dose-response relationship was observed. The positive controls showed distinct biologically relevant effects in mutation frequency. In conclusion, the test substance is considered to be non-mutagenic in the HPRT locus using V79 cells of the Chinese hamster.
All the test results above indicated no genotoxicity potential for the test substance.
Justification for classification or non-classification
Based on the findings of the genetic toxicity studies, the test substance does not considered to be classified according to the EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.